Treatment Dynamics and Challenges of HER2+ Breast Cancer

A recent Peer Exchange discussion featured Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO. O’Shaughnessy and Rugo delved into the HER2CLIMB-02 trial, outlining its key findings and assessing its place in the treatment landscape. The trial, carried out in a previous period, focused on a second-line scenario, pitting T-DM1 (trastuzumab emtansine) plus or minus tucatinib in HER2-positive breast cancer patients. The results showcased a notable progression-free survival boost, particularly in individuals with brain metastases. Notably, the trial boasted a diverse patient pool with varying prior therapy experiences.

Isaacs underscored the significance of survival statistics and favored the HER2CLIMB regimen due to its well-established phase 3 trial. Rugo provided context on the trial, underscoring the evolving treatment environment and the global necessity for access to effective treatments.

The video synopsis was AI-generated and vetted by OncLive® editorial experts.